Idogen publishes prospectus in connection with the forthcoming rights issue

The Board of Directors of Idogen AB (“Idogen” or the “Company”) has, due to the Company’s forthcoming rights issue that was announced on January 28, 2020 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”) which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus is available on the Company’s website (www.idogen.com), on Erik Penser Bank’s website (www.penser.se) and on Spotlight Stock Market’s website (www.spotlightstockmarket.com).

Publication of Prospectus
The Prospectus has been prepared due to the forthcoming Rights Issue and has today, on February 28, 2020, been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus, including full terms and conditions, and subscription forms are available on the Company’s website (www.idogen.com), on Erik Penser Bank’s website (www.penser.se) and on Spotlight Stock Market’s website (www.spotlightstockmarket.com). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). In connection with the commencement of the subscription period in the Rights Issue, a summarizing folder will be sent by mail to Idogen’s direct and nominee-registered shareholders.

The Rights Issue in summary
- The right to subscribe for shares in the Rights Issue, with preferential rights, shall vest in those who were registered as shareholders in the Company on the record date, February 26, 2020, whereby one (1) existing share in the Company entitles to one (1) subscription right and one (1) subscription right entitles to subscription of one (1) new share.
- The subscription price amounts to SEK 0.60 per share, which implies that the Company receives gross proceeds of approximately SEK 29 million before issue costs. The issue costs are estimated to amount to approximately SEK 5 million.
- The Company has received subscription intentions and underwriting commitments of up to 88 percent of the Rights Issue, corresponding to approximately SEK 25.6 million.
- The subscription period in the Rights Issue takes place during the period from and including March 2, 2020 to and including March 16, 2020.
- The last day for trading in Idogen’s share, including the right to participate in the Rights Issue, was on February 24, 2020.
- Trading in subscription rights takes place on Spotlight Stock Market during the period from and including March 2, 2020 to and including March 12, 2020. Subscription rights that are not exercised or sold will become invalid and lose their value.

For further information on the Rights Issue, please refer to the published Prospectus.

“The forthcoming Rights Issue has the potential to strengthen Idogen’s capability to become a successful and significant player in the fast-growing cell therapy market. The proceeds from the Rights Issue will mainly be used to take Idogen’s main project IDO 8 to the start of clinical studies and to bring the preclinical work for IDO T to the next level.,” comments Anders Karlsson, CEO of Idogen.
Investor meetings where Idogen’s CEO Anders Karlsson presents the Company

- March 3, 2020, Redeye Investor After Work, Malmö – registration is made on Redeye’s website, http://www.redeye.se
- March 4, 2020, Life Science Day in Gothenburg, Wallenberg’s conference center in connection to Sahlgrenska in Gothenburg
- March 5, 2020, Erik Penser Bank, Apelbergs gatan 27, Stockholm at 12.00 – registration is sent to seminarium@penser.se
- March 12, 2020, Redeye Investor After Work in Gothenburg, Scandic Rubinen at 18.00 – registration is made on Redeye’s website, http://www.redeye.se

For more information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com

This information was submitted for publication, through the agency of the contact person set out above, on February 28, 2020.

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company’s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient’s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Idogen. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in Idogen will only be made through the Prospectus that Idogen has now published.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States, Australia, Canada, Japan or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Idogen have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Idogen have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.

Within the European Economic Area (“EEA”), no public offering of Securities is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in
This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.